WebApr 8, 2024 · Pacylex's technology combines new insights from Dr. Luc Berthiaume of the University of Alberta connecting myristoylation to cancer with a family of high quality myristoylation inhibitors Pacylex licensed from the University of Dundee. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new … WebPacylex Pharmaceuticals, Inc. is a company based in Canada that is exploiting a discovery made in the lab of Dr. Luc Berthiaume at the University of Alberta. He connected certain cancers with abnormalities in a biological process called myristoylation.
Pacylex Presents Updates on the Journey of PCLX-001 to the
WebJun 15, 2024 · Pacylex's technology combines new insights from Dr. Luc Berthiaume of the University of Alberta, connecting myristoylation to cancer, with a family of high quality myristoylation inhibitors Pacylex licensed from the University of Dundee. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new … WebJan 18, 2024 · At the same time, Dr Luc Berthiaume, from the University of Alberta, had a deep understanding of cancers he believed such compounds could work against, but did not have the compounds to prove his theories. “It was therefore serendipitous that Luc was introduced to PCLX-001, then known as DDD86481, at a seminar he gave at Dundee … formula for calculating gross margin percent
Geneviève Guertin on LinkedIn: 363_fr.pdf 24 comments
WebDr. Luc is very casual and approachable. He does go at a fast pace, but emphasis was always on important details. If you want a nice challenge and a feeling of … WebDr. Luc Berthiaume is a Professor of Cell Biology at the University of Alberta, with 28 years of experience studying protein fatty acylation. He has been leading a productive research laboratory at the University of Alberta for 25 years, where he made the important discovery of a potential link between suppression of NMT2, one of two human ... WebDr. Luc Berthiaume, cell biologist at the University of Alberta, and Dr. John Mackey, medical oncologist and researcher at the Cross Cancer Institute have demonstrated … difficult speech is referred to as